Libo Pharma Corp. (TPEX:7888)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
40.00
+0.40 (1.01%)
At close: May 8, 2026
Market Cap3.01B
Revenue (ttm)n/a
Net Income-296.30M
EPS-4.74
Shares Out75.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume37,448
Average Volume41,135
Open39.90
Previous Close39.60
Day's Range39.05 - 40.50
52-Week Range39.00 - 69.00
Betan/a
RSI32.48
Earnings DateJun 18, 2026

About Libo Pharma

Libo Pharma Corp., a clinical-stage biopharmaceutical company, engage in novel therapeutics development in the field of oncology and hematology. The company offers LIB-101, an interleukin-12 (IL-12) cytokine immunotherapy for innate immunity, adaptive immunity, and hematopoiesis. Libo Pharma Corp. was founded in 2017 and is based in Taipei, Taiwan. [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Employees 31
Stock Exchange Taipei Exchange
Ticker Symbol 7888
Full Company Profile

Financial Performance

Financial Statements